Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Tao Zhu, Lihua Hou et al.|The Lancet Respiratory Medicine|2023Cited by 58
Heterologous prime-boost immunization with CoronaVac and ConvideciaJingxin Li, Fengcai Zhu, Pengfei Jin et al.|medRxiv|2021Cited by 33
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Fengcai Zhu, Lihua Hou et al.|Emerging Microbes & Infections|2022Cited by 30
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previouslyLairun Jin, Fengcai Zhu, Lihua Hou et al.|medRxiv|2022Cited by 10
Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized TrialRong Tang, Jingxin Li, Lihua Hou et al.|SSRN Electronic Journal|2022Cited by 3